In the NAFLD-HCC mouse model, the knockout of METTL3 in conjunction with anti-PD-1 therapy synergistically suppressed tumor growth, resulting in a reduction of over 90% in both tumor volume and weight (83). This evidence concerns the gene PDCD1 and metabolic dysfunction-associated steatotic liver disease.